The pathobiologic implications for treatment. Old and new strategies in the treatment of chronic asthma.
An increased understanding of the pathobiology of asthma has led to improved treatment for chronic asthma. This article discusses the old and new strategies of asthma therapy based on a pathobiologic approach. Therapeutic agents discussed include beta-adrenergic agonists, methylxanthines, corticosteroids, cromolyn, nedocromil, leukotriene modifiers, and new investigational agents.
Horiuchi
T
T
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Castro
M
M
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004361:Drug Tolerance; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D058915:Purinergic P1 Receptor Antagonists; D000068299:Salmeterol Xinafoate; D014970:Xanthines / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D005938:Glucocorticoids; D020024:Leukotriene Antagonists; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C008514:methylxanthine; D000068299:Salmeterol Xinafoate; D004205:Cromolyn Sodium; D000420:Albuterol